• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Alphatec Holdings Inc.

    6/11/26 5:01:18 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care
    Get the next $ATEC alert in real time by email
    S-8 1 atec-20260611.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on June 11, 2026

    Registration No. 333-_______

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Alphatec Holdings, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

    Delaware

    20-2463898

    (State or other jurisdiction of incorporation or organization)

    (IRS Employer Identification No.)

    Alphatec Holdings, Inc.

    1950 Camino Vida Roble

    Carlsbad, California 92008

    (Address of Principal Executive Offices) (Zip Code)

    Alphatec Holdings, Inc. 2026 Employee Stock Purchase Plan

    Alphatec Holdings, Inc. 2026 Equity Incentive Plan

    (Full Title of the Plan)

    Tyson E. Marshall, Esq.

    General Counsel and Secretary

    Alphatec Holdings, Inc.

    1950 Camino Vida Roble

    Carlsbad, California 92008

    (Name and Address of Agent for Service)

    (760) 431-9286

    (Telephone Number, Including Area Code, of Agent For Service)

    Copy to:

    Joshua E. Little, Esq.

    Dentons Durham Jones Pinegar P.C.

    192 E. 200 N., Third Floor

    St. George, Utah 84770

    (435) 674-0400

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x

    Accelerated filer o

    Non-accelerated filer o

    Smaller reporting company o

    Emerging growth company o

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     


     


    EXPLANATORY NOTE

    This Registration Statement registers the offer and sale of (i) up to 2,000,000 shares of common stock, $0.0001 par value per share (“Common Stock”), of Alphatec Holdings, Inc. (the “Company”) that may be issued to participants pursuant to the Alphatec Holdings, Inc. 2026 Employee Stock Purchase Plan (the “Purchase Plan”), and (ii) up to 12,000,000 shares of Common Stock that may be issued to participants pursuant to the Alphatec Holdings, Inc. 2026 Equity Incentive Plan (the “Equity Plan,” and, together with the Purchase Plan, the “Plans”).

    In accordance with the instructional Note to Part I of Form S-8 as promulgated by the Securities and Exchange Commission (the “Commission”), the information specified by Part I of Form S-8 has been omitted from this Registration Statement for offers of Common Stock pursuant to the Purchase Plan and the Equity Plan. The documents containing the information specified in Part I will be delivered to the participants in the Purchase Plan and the Equity Plan covered by this Registration Statement as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). The Company does not need to file these documents with the Commission either as a part of this Registration Statement or in a prospectus or prospectus supplement pursuant to Rule 424 of the Securities Act.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    In accordance with the rules and regulations of the Commission, the information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement or in a prospectus or prospectus supplement pursuant to Rule 424 of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed with the Commission are incorporated by reference in this Registration Statement:

    •
    The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 24, 2026;
    •
    The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Commission on May 5, 2026;
    •
    The Company’s Current Reports on Form 8-K filed with the Commission on January 12, 2026, February 24, 2026, March 3, 2026, May 5, 2026 and June 11, 2026;
    •
    The Company’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 29, 2026; and
    •
    The description of the Company’s Common Stock contained in the Company’s Annual Report on Form 10-K (File No. 000-52024), filed with the Commission on March 17, 2020, including any amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

     


     

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law (the “DGCL”) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as directors or officers to a corporation. The indemnity may cover expenses, including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as directors and officers, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

    The Company has adopted provisions in its Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws that limit or eliminate the personal liability of directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to the Company or its stockholders for monetary damages for any breach of fiduciary duties as a director, except liability for: (i) any breach of the director’s duty of loyalty to the Company or its stockholders; (ii) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or (iv) any transaction from which the director derived an improper personal benefit. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

    The Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that the Company is required to indemnify its directors and officers to the fullest extent authorized by the DGCL against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such person. The Company’s Amended and Restated Bylaws also provide that the Company shall pay the expenses (including attorneys’ fees) incurred by a director or officer in defending any proceeding in advance of its final disposition upon delivery of an undertaking to repay all amounts so advanced if it is ultimately determined that such person is not entitled to indemnification. The Company may purchase and maintain insurance on behalf of any director, officer, employee or agent of the Company against any liability asserted against such person and incurred in such capacity, whether or not the Company would have the power to indemnify such person against such liability under the DGCL.

    The Company has entered into indemnification agreements with each of its directors and executive officers. These agreements, among other things, require the Company to indemnify these individuals for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in the right of the Company, on account of any services undertaken by such person on behalf of the Company or that person’s status as a member of the Company’s board of directors to the maximum extent allowed under Delaware law.

    The Company maintains a directors’ and officers’ liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses the Company for those losses for which the Company has lawfully indemnified the directors and officers. The policy contains various exclusions.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    A list of exhibits included as part of this Registration Statement is set forth in the Exhibit Index to this Registration Statement and is incorporated herein by reference.

     

     

     


     

    Item 9. Undertakings.

    (a)
    The undersigned Registrant hereby undertakes:
    (1)
    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i)
    To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
    (ii)
    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii)
    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement.

    (2)
    That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California, on June 11, 2026.

    ALPHATEC HOLDINGS, INC.

     

     

    By:

    /s/ Patrick S. Miles

     

    Patrick S. Miles

     

    Chairman and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Alphatec Holdings, Inc. (the “Company”), hereby severally constitute and appoint Patrick S. Miles and J. Todd Koning, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Registration Statement, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in such capacities to enable the Company to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature

    Title(s)

    Date

     

     

     

    /s/ Patrick S. Miles

    Patrick S. Miles

    Chairman and Chief Executive Officer

    (Principal Executive Officer)

    June 11, 2026

     

     

     

    /s/ J. Todd Koning

    J. Todd Koning

    EVP, Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

    June 11, 2026

     

     

     

     

     

     

    /s/ Mortimer Berkowitz III

    Mortimer Berkowitz III

    Director

    June 11, 2026

     

     

     

     

    /s/ Quentin Blackford

    Quentin Blackford

    Director

    June 11, 2026

     

     

     

     

     

    /s/ DAVE DEMSKI

    Dave Demski

    Director

    June 11, 2026

     

     

     

    /s/ Karen McGinnis

    Karen McGinnis

    Director

    June 11, 2026

     

     

     

     

    /s/ David Pelizzon

    David Pelizzon

     

    Director

     

    June 11, 2026

     

     

     

     

    /s/ KEITH VALENTINE

    Keith Valentine

    Director

    June 11, 2026

     

     

     

     

     

     

     

     

     

     


     

    INDEX TO EXHIBITS FILED WITH FORM S-8 REGISTRATION STATEMENT

     

    Exhibit Number

     

    Exhibit Description

     

    Filed with this Report

     

    Incorporated by Reference herein from Form or Schedule

     

    Filing Date

     

    SEC File/Reg. Number

    5.1

     

    Opinion of Dentons Durham Jones Pinegar P.C.

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    10.1*

    2026 Equity Incentive Plan

    Form 8-K

    (Exhibit 10.1)

    06/11/26

    000-52024

     

     

     

     

     

     

     

     

     

     

     

    10.2*

    2026 Employee Stock Purchase Plan

    Form 8-K

    (Exhibit 10.2)

    06/11/26

    000-52024

     

     

     

     

     

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2

     

    Consent of Dentons Durham Jones Pinegar P.C. (included in Exhibit 5.1)

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1

     

    Power of Attorney (included on signature page)

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    107

     

    Filing Fee Table

     

    X

     

     

     

     

     

     

     

     


    Get the next $ATEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATEC

    DatePrice TargetRatingAnalyst
    10/28/2025$20.00Buy
    Stifel
    10/24/2025$19.00Overweight
    Analyst
    6/16/2025$18.00Buy
    Lake Street
    8/1/2024Overweight → Equal-Weight
    Morgan Stanley
    7/8/2024$19.00Overweight
    Barclays
    2/9/2024$26.00Overweight
    Wells Fargo
    12/19/2023$16.00 → $18.00Buy
    Needham
    10/20/2023$22.00Buy
    ROTH MKM
    More analyst ratings

    $ATEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcginnis Karen K was granted 32,012 shares and sold $48,460 worth of shares (6,050 units at $8.01) as part of a pre-agreed trading plan, increasing direct ownership by 38% to 94,671 units (SEC Form 4) to cover withholding tax

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    6/12/26 5:54:14 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Blackford Quentin S. was granted 32,012 shares, increasing direct ownership by 6% to 600,381 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    6/12/26 5:34:58 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Valentine Keith was granted 32,012 shares, increasing direct ownership by 14% to 264,283 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    6/12/26 5:30:14 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Alphatec with a new price target

    Stifel resumed coverage of Alphatec with a rating of Buy and set a new price target of $20.00

    10/28/25 7:09:19 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Alphatec with a new price target

    Analyst initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00

    10/24/25 8:59:42 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Lake Street resumed coverage on Alphatec with a new price target

    Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00

    6/16/25 8:53:19 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Valentine Keith bought $996,192 worth of shares (135,000 units at $7.38), increasing direct ownership by 139% to 232,271 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    5/11/26 7:00:05 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Bakst Evan bought $201,600 worth of shares (35,000 units at $5.76) (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/26/24 4:32:07 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Pelizzon David R bought $149,998 worth of shares (25,796 units at $5.81), increasing direct ownership by 8% to 331,696 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/26/24 4:27:25 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    SEC Filings

    View All

    SEC Form S-8 filed by Alphatec Holdings Inc.

    S-8 - Alphatec Holdings, Inc. (0001350653) (Filer)

    6/11/26 5:01:18 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Alphatec Holdings Inc.

    144 - Alphatec Holdings, Inc. (0001350653) (Subject)

    6/11/26 11:04:34 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Alphatec Holdings Inc.

    SD - Alphatec Holdings, Inc. (0001350653) (Filer)

    5/28/26 4:52:07 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Financials

    Live finance-specific insights

    View All

    ATEC to Report First Quarter 2026 Financial Results on May 5, 2026

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2026 financial results on May 5, 2026, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations section of ATEC's corporate website. Analyst Participation To participate in the question-and-answer session, analysts must register in advance using this link. Upon registration, access details, including a unique code, will be provided via email. Replay A replay of the webcast will remai

    4/23/26 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook

    Full-year 2025 total revenue grew 25% to approximately $764 million Expect full-year 2026 total revenue of $890 million Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2025. The Company also provided a financial outlook for full-year 2026. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Select Financial Results   Fourth Quarter Ended December 31, 2025 Full Year Ended December 31, 2025 Surgical Revenue $189.3M to $190.0M $686.3M to

    1/12/26 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC to Report Third Quarter 2025 Financial Results on October 30, 2025

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2025 financial results on October 30, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations section of ATEC's corporate website. Dial-In To dial into the live webcast, please register at this link. Access details will be provided via email. Replay A replay of the webcast will remain available through the Investor Relations section of ATEC's corporate website for twelve month

    10/16/25 4:10:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATEC Refinances Existing Debt with Inaugural Bank Facility

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced it has entered into a new credit facility, including a $125 million revolving credit facility and $175 million Term Loan A, led by JPMorgan Chase Bank, N.A. and TD Securities (USA) LLC. This transaction represents ATEC's inaugural syndicated bank facility and reflects the Company's strong operating performance and continued progression to a more scaled and profitable financial profile. The new facility refinances the Company's existing debt, including its prior term loan and asset-based lending facilities with Braidwell LP, Pha

    5/5/26 4:05:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC Reports First Quarter Financial Results

    Surgical revenue grew 17%; total revenue grew 14% Company announces refinancing of existing debt with inaugural bank facility, reducing interest expense by more than $6 million annually and extending maturities to 2031 Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2026, and business highlights. First Quarter 2026 Financial Results Quarter Ended March 31, 2026 Total revenue $192 million GAAP gross margin 71% Non-GAAP gross margin 72% GAAP operating expenses

    5/5/26 4:05:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC to Report First Quarter 2026 Financial Results on May 5, 2026

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2026 financial results on May 5, 2026, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations section of ATEC's corporate website. Analyst Participation To participate in the question-and-answer session, analysts must register in advance using this link. Upon registration, access details, including a unique code, will be provided via email. Replay A replay of the webcast will remai

    4/23/26 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Alphatec Holdings Inc.

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    11/12/24 8:04:57 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    3/22/24 7:57:56 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    5/12/23 4:51:18 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Leadership Updates

    Live Leadership Updates

    View All

    ATEC Mourns Passing of Board Member Jeffrey P. Rydin

    Alphatec Holdings, Inc. (NASDAQ:ATEC) ("ATEC"), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced with great sadness that Jeffrey P. Rydin, a valued member of its Board of Directors, has passed away at age 59, following a lengthy illness. Mr. Rydin enjoyed nearly three decades of experience in the medical device and healthcare industries, including senior sales leadership roles at Ellipse Technologies, Inc., NuVasive, Inc., and DePuy Spine, Inc. He was one of the earliest to join the ATEC turnaround effort, coming to the Company as a Special Advisor to the Board in September 2016, in which capacity he drove many of the early deci

    11/7/25 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Paragon 28 Appoints Dave Demski to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

    12/11/24 9:00:00 AM ET
    $ATEC
    $FNA
    Medical/Dental Instruments
    Health Care

    Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

    Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri

    4/4/24 9:05:00 AM ET
    $ATEC
    $SYK
    Medical/Dental Instruments
    Health Care